Sign in

You're signed outSign in or to get full access.

Hilary Kramer

Director at GT Biopharma
Board

About Hilary Kramer

Hilary Kramer (age 60) was appointed as a non‑employee director of GT Biopharma on May 7, 2025; she is independent under Nasdaq rules and serves as Chair of the Nominating & Corporate Governance Committee, with memberships on the Audit and Compensation Committees . Kramer is CEO/President/CIO of Greentech Research LLC (since 2006) and previously worked as an analyst and investment banker at Morgan Stanley and Lehman Brothers; she holds an MBA from Wharton and a BA with honors from Wellesley College .

Past Roles

OrganizationRoleTenureCommittees/Impact
Greentech Research LLCCEO, President & CIOSince 2006 Global fund specializing in alternative energies/clean tech
Morgan StanleyAnalyst/Investment bankerNot disclosed Capital markets experience
Lehman BrothersAnalyst/Investment bankerNot disclosed Capital markets experience
Ibero‑American Media Partners II Ltd.Co‑Head & DirectorNot disclosed $1.0B PE fund jointly owned by Hicks, Muse, Tate & Furst
INX Digital CompanyDirectorNot disclosed Board service
RSL Communications, Inc.DirectorNot disclosed Board service
El Sitio Inc.DirectorNot disclosed Board service
Deltathree Inc.DirectorNot disclosed Board service
DirectTV Latin AmericaDirectorNot disclosed Board service

External Roles

OrganizationRoleStatusNotes
Greentech Research LLCCEO/President/CIOCurrent Alternative energy/clean tech focus
Publications & MediaAuthor & Radio hostCurrent Books, newsletter (GameChangers), Salem Network radio
WSJ Women in BusinessFounding memberPast Network leadership

Board Governance

  • Committee assignments: Audit (member), Compensation (member), Nominating & Corporate Governance (Chair) .
  • Independence: Board determined Kramer is independent per Nasdaq; Audit Committee comprised entirely of independent directors .
  • Board/committee activity baseline: In FY2024, Board met 6 times; Audit met 4, Compensation 1, Nominating 0; each then‑serving director attended ≥75% of meetings (Kramer joined in 2025, so her attendance for 2024 is not applicable) .
  • Board diversity: GTBP has one female director among four total, aligning with a stated diversity policy (Kramer is the sole female director) .
  • Risk oversight and leadership: Combined Chair/CEO role; committees oversee compensation risk, financial reporting, and independence/conflicts .

Fixed Compensation

ComponentAmountNotes
Annual cash retainer (Board)$50,000 (FY2024 program) Applies to non‑employee directors; Kramer appointed in 2025; individual 2025 amounts not yet disclosed
Committee membership fees$5,000 per committee per year (FY2024 program) Audit/Compensation/Nominating; Kramer serves on all three
Special Committee fees$8,000 per month (Jan–Feb 2024) Special Committee disbanded Mar 26, 2024

Pearl Meyer engaged Jan 2024 as independent compensation consultant for board program design; Compensation Committee assessed independence and found no conflicts .

Performance Compensation

Equity typeGrant size/termsVestingNotes
Non‑employee director stock options (FY2023 practice)16,666 options per director 1/12 monthly vesting from grant date; subject to acceleration Program precedent; Kramer’s specific 2025 equity grants not disclosed
Equity plan capacity2022 Plan increased to 750,000 authorized shares via Amendment No. 1 (pending shareholder approval July 24, 2025) N/AOverhang projected at 23.8% of shares outstanding; options outstanding 124,600 at 5/30/2025
Exercise price examples$10.50, $25.50, $74.40 (various director options) N/AWeighted average exercise price for options under 2022 Plan was $32.69 at 12/31/2024

Performance metrics tied to director compensation: None disclosed; director equity awards are time‑vested without explicit performance metrics .

Other Directorships & Interlocks

CompanyRolePotential Interlock/Conflict
INX Digital CompanyDirector (past) No GTBP related‑party link disclosed
RSL Communications, Inc.Director (past) No GTBP related‑party link disclosed
El Sitio Inc.Director (past) No GTBP related‑party link disclosed
Deltathree Inc.Director (past) No GTBP related‑party link disclosed
DirectTV Latin AmericaDirector (past) No GTBP related‑party link disclosed

No current public company boards for Kramer were disclosed beyond GTBP .

Expertise & Qualifications

  • Capital markets and PE: Prior analyst/banker at Morgan Stanley/Lehman; co‑head of a $1.0B PE fund (Ibero‑American Media Partners II) .
  • Energy/technology investing: Leads Greentech Research LLC; deep exposure to alternative energy and clean technology .
  • Communication/insights: Author of multiple investment books/newsletters; syndicated radio show; founding member, WSJ Women in Business .
  • Education: MBA (Wharton), BA with honors (Wellesley) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotes
Hilary Kramer— (not reported) No shares or options reported as beneficially owned within 60 days of 6/10/2025
Hedging/PledgingNoneN/ACompany policy prohibits short sales/derivatives; no hedging/pledging history for non‑employee directors as of proxy date

Vested/unvested breakdown, options in‑the‑money, or pledges for Kramer: Not disclosed in the beneficial ownership table .

Governance Assessment

  • Board effectiveness signal: Kramer chairs Nominating & Corporate Governance, giving her direct influence on board composition, governance policies, and independence oversight—a positive for governance rigor if the committee is active post‑2025 (note: Nominating held zero meetings in FY2024 prior to Kramer’s appointment) .
  • Independence and financial oversight: Independent status and Audit Committee service reinforce investor confidence in reporting integrity; Audit Committee chaired by an experienced financial expert (Casamento) .
  • Ownership alignment: No reported beneficial ownership for Kramer as of 6/10/2025, indicating limited “skin‑in‑the‑game” currently; consider monitoring for equity grants or purchases to improve alignment .
  • Compensation structure: Cash retainer + committee fees and time‑vested options are standard; the absence of performance‑tied metrics for directors is typical but offers limited pay‑for‑performance linkage .
  • Related‑party/Conflict check: No related‑party transactions or pledging/hedging involving Kramer disclosed; major related‑party exposure is to Cytovance (supplier/shareholder), unrelated to Kramer .
  • Dilution risk and board support: Officers and directors entered a Voting Agreement to vote in favor of a financing‑related issuance beyond Nasdaq 19.99% thresholds; if approved, investors could hold up to 67% voting power, implying substantial dilution/change‑of‑control risk—monitor governance safeguards and independent board oversight of financing terms (Kramer likely party as a director, though she held no reported shares) .

RED FLAGS: Potential shareholder dilution/change‑of‑control from Proposal No. 4; combined Chair/CEO role concentrates power; limited director equity ownership for Kramer reduces alignment until grants/purchases occur .